MONOS ® - Rufloxacin

MONOS ® is a drug based on Rufloxacin hydrochloride

THERAPEUTIC GROUP: Antibacterial for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications MONOS ® - Rufloxacin

MONOS ® is an antibiotic used clinically to treat infections of the respiratory tract and the genitourinary tract supported by microorganisms sensitive to Rufloxacin.

Mechanism of action MONOS ® - Rufloxacin

MONOS ® is an antibiotic based on Rufloxacin, an active ingredient belonging to the fluoroquinolone category, with which it shares the same mechanism of action despite having particularly advantageous pharmacokinetic characteristics.

Taken orally, in fact, Rufloxacin is rapidly absorbed from the gastro-intestinal tract, concentrating in clinically relevant quantities in the tissues and in particular in the lung and genitourinary level, where it carries out its therapeutic activity for over 24 hours.

The long half-life and the broad spectrum of action make it possible to limit the intake of MONOS ® to once a day, thus improving therapeutic compliance in affected patients, and therefore also its therapeutic efficacy.

The microbicidal activity of Rufloxacin, takes the form of inhibition of the activities of some enzymes involved in the DNA replication mechanism, such as bacterial DNA gyrase, whose blockage results in the death of the pathogenic microorganism.

At the end of its long half-life, Rufloxacin is eliminated mainly via the kidney and to a minimal extent via the bile following a moderate hepatic metabolism.

Studies carried out and clinical efficacy

RUFLOXACINA IN THE ERADICATION OF H.PYLORI

Helicobacter. 2011 Aug; 16 (4): 284-8.

Study that evaluates the importance of the pharmacological approach to H. Pylori infection, demonstrating how quadruple therapy also containing Rufloxacin can be effective in eradicating the microorganism from the gastric mucosa.

PHOTOTOXICITY BY RUFLOXACINA

Mutat Res. 2010 Oct 13; 692 (1-2): 34-41.

An interesting study that tests, through experimental models, the photosensitizing role of Rufloxacin, demonstrating the phototoxic and photomutagenous potential of this antibiotic, even on simple cellular models such as yeast.

RUFLOXACINE IN PRE-OPERATIVE PROPHYLAXIS

Arch Ital Urol Androl. 2000 Apr; 72 (1): 15-20.

Work demonstrating that the use of a single oral dose of Rufloxacin may be useful in common clinical practice as preoperative antibiotic prophylaxis in urological clinic, given the low management costs and documented effectiveness.

Method of use and dosage

MONOS ®

Rufloxacin hydrochloride 200 mg coated tablets

Therapy with MONOS ® should be defined by your doctor based on the patient's physiopathological conditions and the severity of the clinical picture present.

As a general rule, thanks to the long half-life of Rufloxacin, the single administration of one or two tablets would be sufficient, depending on the patient's needs for a variable duration linked to the remission of symptoms.

An adjustment of the dosages used should also be provided for patients suffering from kidney disease or in elderly patients.

Warnings MONOS ® - Rufloxacin

Given the potential side effects associated with fluoroquinolone therapy, it would be advisable to undergo a careful medical examination before starting therapy with MONOS ®.

In fact, it is important to remember that therapy with fluoroquinolones may induce tendinitis in elderly or predisposed patients, photosensitization and heart disease.

In this regard, therefore, maximum caution is recommended in the administration of this drug in patients potentially susceptible to side effects as well as in elderly patients or patients with impaired renal function, given the reduced ability to eliminate the drug.

Prolonged use of MONOS ® could lead to the appearance of persistent diarrhea, linked to infections caused by germs resistant to drug therapy and thus facilitate the spread of multi-resistant microbial strains, responsible for usually more serious clinical pictures.

PREGNANCY AND BREASTFEEDING

The insufficiency of accessible data, able to fully characterize the safety profile of Rufloxacin for the health of the fetus and infant, extends the aforementioned contraindications to the use of the drug also to pregnancy and the subsequent period of breastfeeding.

Interactions

In order to minimize pharmacologically relevant interactions responsible for potentially dangerous clinical pictures it would be advisable to avoid the simultaneous intake of Rufloxacin and antacids, quinolones and NSAIDs due to the risk of unpleasant adverse reactions rather than significant alterations of the therapeutic properties of the drug.

Contraindications MONOS ® - Rufloxacin

The use of MONOS ® is contraindicated in patients hypersensitive to the active substance or to any of its excipients, in children, in patients predisposed or with a previous history of neurological and cardiac pathologies.

Undesirable effects - Side effects

The use of MONOS ® could cause the appearance of abdominal pain accompanied by nausea, heartburn, dyspepsia, diarrhea and vomiting, alterations of the central nervous system with headache, agitation, anxiety, dizziness, insomnia and fatigue and only rarely hypersensitivity reactions sometimes severe from a clinical point of view.

Side effects at the tendon level were very rare, affecting mostly high-risk patients.